- Investing.com
XORTX Therapeutics Inc., a late stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, pre-diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, a program to treat acute kidney injury (AKI) associated with respiratory virus infection and associated health consequences; and XRX-225, a program for treatment of type 2 diabetic nephropathy. It has a collaboration and license agreements with the Icahn School of Medicine; and a license agreement with the University of Florida Research Foundation, Inc. The company is based in Alberta Beach, Canada.
Metrics to compare | XRTX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipXRTXPeersSector | |
---|---|---|---|---|
P/E Ratio | −4.2x | −3.4x | −0.6x | |
PEG Ratio | −0.05 | −0.06 | 0.00 | |
Price/Book | 1.4x | 0.3x | 2.6x | |
Price / LTM Sales | - | 1.3x | 3.1x | |
Upside (Analyst Target) | - | 51.3% | 48.8% | |
Fair Value Upside | Unlock | 9.0% | 7.5% | Unlock |